Breast Cancer Clinical Trials in Dallas

Showing 421-440 of 593 trials

Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET

NCT03065712

This study will formally address the hypothesis that FES-PET/CT measurement of ER expression predicts clinical benefit of first-line endocrine therapy in newly diagnosed ER+ metastatic breast cancer patients and establishes the repeatability of FES PET/CT.

Breast Cancer

University of Texas Southwestern Medical CenterStarted Feb 2017

Dallas, Texas, United States

COMPLETEDPhase 2< 1 mile

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

NCT00684983

This phase II trial studies capecitabine and lapatinib ditosylate to see how well they work compared with capecitabine, lapatinib ditosylate, and cixutumumab in treating patients with previously treated HER2-positive stage IIIB-IV breast cancer. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with cixutumumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether capecitabine and lapatinib ditosylate are more effective when given with or without cixutumumab in treating breast cancer that has spread nearby or to other areas of the body.

HER2 Positive Breast CarcinomaRecurrent Breast CarcinomaStage IIIB Breast Cancer AJCC v7+2 more

National Cancer Institute (NCI)64 participantsStarted Jul 2008

Mobile, Alabama, United States • Scottsdale, Arizona, United States • Berkeley, California, United States +387 more locations

Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

Breast Cancer Trials in Other Cities

A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

MRI to Detect Breast Tumors in Women

MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer

A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Vaccine Therapy in Treating Patients With Breast Cancer

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Health Benefits of Expressive Writing: Study One

Health Benefits of Expressive Writing Among Chinese Breast Cancer Survivors

A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer

Combination Chemotherapy in Treating Patients With Breast Cancer

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide

Other Conditions in Dallas